On July 21st, 2021, Curogen Co., Ltd. – SKKU – Masan National Tuberculosis Hospital signed a tri-party MOU on researching on possible COVID19 treatment substances.

Masan National Tuberculosis Hospital was established to contribute to curing multiple drug resistance tuberculosis with 354 wards, including isolation and research wards, and special research facilities. The hospital conducts research on contagious diseases under thorough infection control.

According to this agreement, the three organizations will conduct COVID19 antiviral efficacy tests on Curogen’s drug candidate at Masan National Tuberculosis Hospital.